SPY425.26+0.95 0.22%
DIA344.30-0.82 -0.24%
IXIC14,174.14+104.72 0.74%

Axcella Health Initiates Phase 2b Trial of AXA1125 to Treat Nonalcoholic Steatohepatitis

05/11/2021 03:59

07:59 AM EDT, 05/11/2021 (MT Newswires) -- Axcella Health (AXLA) has initiated a phase 2b clinical trial of AXA1125, the company's drug candidate to treat nonalcoholic steatohepatitis, or NASH.

The trial will be conducted at more than 70 clinical sites and enroll 270 patients, and the primary endpoint will assess the proportion of patients with a biopsy-confirmed 2 point or greater improvement in NAFLD Activity Score after 48 weeks of treatment.

Price: 3.4400, Change: -0.2300, Percent Change: -6.27